Skip to main content
. 2021 Apr 16;11:656325. doi: 10.3389/fonc.2021.656325

Table 4.

Clinical characteristic of patients in training set and validation set.

Characteristics Total N = No. (%) Training Set N = No. (%) Validation Set N = No. (%) P-value
PRIMARY ORGAN 0.351
bladder 40 (21.3) 31 (24.8) 9 (14.3)
Kidney 49 (26.1) 28 (22.4) 21 (33.3)
Other 13 (6.9) 9 (7.2) 4 (6.3)
Paratesticular 56 (29.8) 36 (28.8) 20 (31.7)
Prostate 30 (16.0) 21 (16.8) 9 (14.3)
GENDER 0.295
Female 46 (24.5) 34 (27.2) 12 (19.0)
Male 142 (75.5) 91 (72.8) 51 (81.0)
AGE 0.842
>50 years 75 (39.9) 51 (40.8) 24 (38.1)
≤50 years 113 (60.1) 74 (59.2) 39 (61.9)
PRESENTING SYMPTOMS 0.283
Asymptomatic 9 (4.8) 4 (3.2) 5 (7.9)
Symptomatic 179 (95.2) 121 (96.8) 58 (92.1)
SYMPTOMATIC DURATION 0.906
>1 month 116 (61.7) 78 (62.4) 38 (60.3)
≤1 month 72 (38.3) 47 (37.6) 25 (39.7)
TUMOR SIZE 0.287
>5 cm 150 (79.8) 103 (82.4) 47 (74.6)
≤5 cm 38 (20.2) 22 (17.6) 16 (25.4)
HISTOLOGICAL SUBTYPE 0.881
Liposarcoma 38 (20.2) 27 (21.6) 11 (17.5)
Leiomyosarcoma 77 (41.0) 51 (40.8) 26 (41.3)
Other 37 (19.7) 23 (18.4) 14 (22.2)
Rhabdomyosarcoma 36 (19.1) 24 (19.2) 12 (19.0)
METASTASIS_AT_ENTRY 0.836
no 140 (74.5) 92 (73.6) 48 (76.2)
yes 48 (25.5) 33 (26.4) 15 (23.8)
GRADE 0.314
high 152 (80.9) 98 (78.4) 54 (85.7)
low 36 (19.1) 27 (21.6) 9 (14.3)
SURGERY_STATUS 0.585
Surgery and margin negative 106 (63.5) 69 (61.1) 37 (68.5)
No Surgery 33 (19.8) 23 (20.4) 10 (18.5)
Surgery and margin positive 28 (16.8) 21 (18.6) 7 (13.0)
CHEMOTHERAPY 0.472
no 51 (28.3) 36 (30.5) 15 (24.2)
yes 129 (71.7) 82 (69.5) 47 (75.8)
RADIOTHERAPY 0.467
no 114 (63.3) 72 (61.0) 42 (67.7)
yes 66 (36.7) 46 (39.0) 20 (32.3)

Other in Primary organ included four genitourinary sites: ureter, seminal vesicles, and urethra. Other in histological subtype included Ewing′s sarcoma, primitive neuroectodermal tumor, synovial sarcoma, angiosarcoma, fibrosarcoma, malignant peripheral sheath tumor, myo-fibroblastic tumor, osteosarcoma, chondrosarcoma, and undifferentiated sarcoma.